Beximco Pharma commences export to Kuwait

For the first time, a Bangladeshi pharmaceutical company has launched drug products in a Gulf member country

Beximco Pharmaceuticals, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has commenced the export of pharmaceuticals to Kuwait. This marks the first time a Bangladeshi pharmaceutical company has launched drug products in any Gulf member country under the Gulf Co-Operation Council (GCC).

A launch ceremony was held at Beximco Pharma’s factory in Dhaka to mark the shipment of the first consignment to Kuwait in the presence of the Ambassador of Kuwait, His Excellency Mr Adel Mohammad A.H. Hayat.

Initial exports to Kuwait from Beximco Pharma include two metered-dose inhaler products for asthma and other respiratory conditions, namely Azmasol (Salbutamol), Bexitrol-F (Salmeterol plus Fluticasone) and one blood pressure drug Amdocal (Amlodipine).

The company expects to launch additional products in Kuwait later this year. The combined Gulf market is estimated to be worth $9bn and the Kuwait market alone to be worth $1.5bn.

Managing Director of Beximco Pharma, Nazmul Hassan MP, commented: ‘Beximco Pharma continues to build its presence in emerging and developed markets. The company is increasingly focused on regulated markets, such as the US, EU, GCC and Australia, where the demand for generic pharmaceutical products is rising. The Gulf market is an important market for us and the launch of our products in Kuwait will open up new opportunities in the region. We will continue to expand our product range in the Gulf market, providing patients with safe and affordable treatment options.’

Beximco Pharma is the largest exporter of pharmaceuticals in Bangladesh, winning the country’s National Export Trophy a record five times, the highest national accolade for export. The company currently has a global footprint in more than 50 countries and has been accredited by a number of global regulatory authorities, including the US FDA, AGES (EU), TGA Australia, Health Canada, GCC and TFDA.